Reading view
AeroTherm-GPT: A Verification-Centered LLM Framework for Thermal Protection System Engineering Workflows
ReFlow: Self-correction Motion Learning for Dynamic Scene Reconstruction
DWDP: Distributed Weight Data Parallelism for High-Performance LLM Inference on NVL72
GPA: Learning GUI Process Automation from Demonstrations
Reflection of Episodes: Learning to Play Game from Expert and Self Experiences
Learn to Relax with Large Language Models: Solving Constraint Optimization Problems via Bidirectional Coevolution
Stabilizing Rubric Integration Training via Decoupled Advantage Normalization
NCCL EP: Towards a Unified Expert Parallel Communication API for NCCL
Generation Is Compression: Zero-Shot Video Coding via Stochastic Rectified Flow
UniMixer: A Unified Architecture for Scaling Laws in Recommendation Systems
A high-throughput selection system for fast-acting covalent protein drugs
Functional RNA splitting drove the evolutionary emergence of type V CRISPR-Cas systems from transposons
Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias
Genetically encoded fluorescent reporters to visualize α-synuclein pathology in live brain
Pyruvate is a natural suppressor of interferon signaling by inducing STAT1 protein pyruvylation
The neonatal lung microbiome: a dynamic determinant of respiratory health, disease, and novel therapeutics
Front Pediatr. 2026 Mar 16;14:1770578. doi: 10.3389/fped.2026.1770578. eCollection 2026.
ABSTRACT
The neonatal lung, once considered sterile, is now recognized to harbor a dynamic and complex microbiome that plays a critical role in respiratory health and disease. This review synthesizes current evidence on the composition, development, and functional impact of the lung microbiome in neonates, with a focus on its involvement in key respiratory disorders such as bronchopulmonary dysplasia, respiratory syncytial virus infection, neonatal acute respiratory distress syndrome, cystic fibrosis, and asthma predisposition. We place particular emphasis on the bidirectional communication along the gut-lung axis as a central mechanism, wherein intestinal microbiota and their metabolites modulate pulmonary immunity and inflammation. Emerging multi-omics studies that integrate microbial data with host metabolomic and immune profiles are highlighted for their role in deciphering disease-specific dysbiotic signatures and mechanistic pathways. Critically, this review advances the discussion beyond association by evaluating the translational potential of the microbiome as both a diagnostic biomarker and a therapeutic target. We provide a critical appraisal of innovative microbiome-targeted strategies-including probiotics, postbiotics, phage therapy, and bacterial lysates-and discuss the unique challenges and future directions for translating these approaches into safe, effective clinical interventions for vulnerable neonates. By bridging foundational science with clinical implications, this work aims to inform the development of novel, ecology-informed therapeutics to prevent and mitigate neonatal respiratory diseases.
PMID:41918694 | PMC:PMC13033698 | DOI:10.3389/fped.2026.1770578
The neonatal lung microbiome: a dynamic determinant of respiratory health, disease, and novel therapeutics
Front Pediatr. 2026 Mar 16;14:1770578. doi: 10.3389/fped.2026.1770578. eCollection 2026.
ABSTRACT
The neonatal lung, once considered sterile, is now recognized to harbor a dynamic and complex microbiome that plays a critical role in respiratory health and disease. This review synthesizes current evidence on the composition, development, and functional impact of the lung microbiome in neonates, with a focus on its involvement in key respiratory disorders such as bronchopulmonary dysplasia, respiratory syncytial virus infection, neonatal acute respiratory distress syndrome, cystic fibrosis, and asthma predisposition. We place particular emphasis on the bidirectional communication along the gut-lung axis as a central mechanism, wherein intestinal microbiota and their metabolites modulate pulmonary immunity and inflammation. Emerging multi-omics studies that integrate microbial data with host metabolomic and immune profiles are highlighted for their role in deciphering disease-specific dysbiotic signatures and mechanistic pathways. Critically, this review advances the discussion beyond association by evaluating the translational potential of the microbiome as both a diagnostic biomarker and a therapeutic target. We provide a critical appraisal of innovative microbiome-targeted strategies-including probiotics, postbiotics, phage therapy, and bacterial lysates-and discuss the unique challenges and future directions for translating these approaches into safe, effective clinical interventions for vulnerable neonates. By bridging foundational science with clinical implications, this work aims to inform the development of novel, ecology-informed therapeutics to prevent and mitigate neonatal respiratory diseases.
PMID:41918694 | PMC:PMC13033698 | DOI:10.3389/fped.2026.1770578